Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
Crossref DOI link: https://doi.org/10.1186/s40164-016-0039-0
Published Online: 2016-04-11
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Liu, Jun S.
Rao, Sumati
Funding for this research was provided by:
Bristol-Myers Squibb
